Khandan Keyomarsi

14.0k total citations · 4 hit papers
158 papers, 10.7k citations indexed

About

Khandan Keyomarsi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Khandan Keyomarsi has authored 158 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Oncology, 73 papers in Molecular Biology and 45 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Khandan Keyomarsi's work include Cancer-related Molecular Pathways (89 papers), Advanced Breast Cancer Therapies (43 papers) and Microtubule and mitosis dynamics (33 papers). Khandan Keyomarsi is often cited by papers focused on Cancer-related Molecular Pathways (89 papers), Advanced Breast Cancer Therapies (43 papers) and Microtubule and mitosis dynamics (33 papers). Khandan Keyomarsi collaborates with scholars based in United States, United Kingdom and France. Khandan Keyomarsi's co-authors include Arthur B. Pardee, Timothy M. Pawlik, Kelly K. Hunt, Thaddeus W Herliczek, J. Wade Harper, Michael Lowe, Stephen J. Elledge, Saïd Akli, Ruth Sager and Tuyen Bui and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Khandan Keyomarsi

155 papers receiving 10.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of cyclin-dependent kinases by p21.

1995 855 citations Khandan Keyomarsi et al. profile →
Role of cell cycle in mediating sensitivity to radiotherapy

2004 829 citations Khandan Keyomarsi et al. profile →
Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCF ^Fbw7 Ubiquitin Ligase

2001 649 citations Khandan Keyomarsi et al. profile →
Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance

2024 65 citations Mi Li, Khandan Keyomarsi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Khandan Keyomarsi United States	51	6.7k	5.5k	2.2k	1.7k	1.7k	158	10.7k
Todd Waldman United States	39	8.0k 1.2×	5.7k 1.0×	2.0k 0.9×	1.2k 0.7×	997 0.6×	66	10.9k
Wilhelm Krek Switzerland	52	7.6k 1.1×	3.7k 0.7×	2.3k 1.0×	1.7k 1.0×	1.0k 0.6×	93	10.8k
Göran Landberg Sweden	58	5.6k 0.8×	4.5k 0.8×	3.0k 1.3×	837 0.5×	1.3k 0.8×	211	10.2k
Gary E. Gallick United States	67	7.7k 1.2×	6.0k 1.1×	2.9k 1.3×	1.3k 0.8×	2.0k 1.2×	202	13.7k
Piyush B. Gupta United States	32	7.8k 1.2×	7.1k 1.3×	3.5k 1.6×	1.6k 0.9×	1.1k 0.6×	55	13.1k
Samy Lamouille United States	17	7.4k 1.1×	4.2k 0.8×	3.2k 1.4×	1.2k 0.7×	1.5k 0.9×	24	11.4k
Charlotte Kuperwasser United States	45	6.4k 1.0×	6.8k 1.2×	3.0k 1.4×	1.1k 0.6×	951 0.6×	91	11.1k
Gema Moreno‐Bueno Spain	55	6.2k 0.9×	4.1k 0.7×	2.7k 1.2×	891 0.5×	1.1k 0.7×	142	10.0k
Donna L. George United States	39	8.4k 1.3×	7.0k 1.3×	2.1k 1.0×	991 0.6×	1.1k 0.7×	80	11.7k
Yoshitaka Sekido Japan	69	9.3k 1.4×	3.7k 0.7×	3.3k 1.5×	1.6k 0.9×	3.6k 2.1×	199	14.3k

Countries citing papers authored by Khandan Keyomarsi

Since Specialization

Citations

This map shows the geographic impact of Khandan Keyomarsi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khandan Keyomarsi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khandan Keyomarsi more than expected).

Fields of papers citing papers by Khandan Keyomarsi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khandan Keyomarsi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khandan Keyomarsi. The network helps show where Khandan Keyomarsi may publish in the future.

Co-authorship network of co-authors of Khandan Keyomarsi

This figure shows the co-authorship network connecting the top 25 collaborators of Khandan Keyomarsi. A scholar is included among the top collaborators of Khandan Keyomarsi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khandan Keyomarsi. Khandan Keyomarsi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

House, Nealia C., Maxine Chen, Sima Khazaei, et al.. (2025). CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. npj Breast Cancer. 11(1). 135–135. 1 indexed citations

Li, Mi, Amriti R. Lulla, Spyros Tsavachidis, et al.. (2024). Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Research. 84(22). 3864–3880. 4 indexed citations

Nguyen, Tuyen Duong Thanh, Tuyen Bui, Rossana Lazcano, et al.. (2023). Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Research. 83(6). 939–955. 3 indexed citations

Ha, Min Jin, Akshara Singareeka Raghavendra, Nicole M. Kettner, et al.. (2022). Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study. International Journal of Cancer. 150(12). 2025–2037. 27 indexed citations

Carey, Jason P.W., Cansu Karakaş, Tuyen Bui, et al.. (2017). Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Research. 78(3). 742–757. 103 indexed citations

Doostan, Iman, Cansu Karakaş, Matthew J. Ellis, et al.. (2017). Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clinical Cancer Research. 23(23). 7288–7300. 35 indexed citations

Francis, Ashleigh M., Angela Alexander, Yanna Liu, et al.. (2017). CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Molecular Cancer Therapeutics. 16(9). 1751–1764. 41 indexed citations

Chen, Xian, Tuyen Bui, Yufeng Jiang, et al.. (2016). Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 15(4). 593–607. 51 indexed citations

Hunt, Kelly K., Cansu Karakaş, Min Jin Ha, et al.. (2016). Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clinical Cancer Research. 23(12). 2991–3002. 49 indexed citations

10.

Doostan, Iman, Cansu Karakaş, Tuyen Bui, et al.. (2016). Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Research. 76(8). 2406–2418. 75 indexed citations

11.

Duong, MyLinh, Saïd Akli, Anna Biernacka, et al.. (2013). Hbo1 Is a Cyclin E/CDK2 Substrate That Enriches Breast Cancer Stem-like Cells. Cancer Research. 73(17). 5556–5568. 38 indexed citations

12.

Bagheri‐Yarmand, Rozita, Anna Biernacka, Kelly K. Hunt, & Khandan Keyomarsi. (2010). Low Molecular Weight Cyclin E Overexpression Shortens Mitosis, Leading to Chromosome Missegregation and Centrosome Amplification. Cancer Research. 70(12). 5074–5084. 45 indexed citations

13.

Delk, Nikkí A., Kelly K. Hunt, & Khandan Keyomarsi. (2009). Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation. Cancer Research. 69(7). 2817–2825. 36 indexed citations

14.

Agarwal, Roshan, Simen Myhre, Mark Carey, et al.. (2009). Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. Clinical Cancer Research. 15(11). 3654–3662. 111 indexed citations

15.

Şahin, Ayşegül A., et al.. (2008). Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Research and Treatment. 115(3). 651–659. 28 indexed citations

16.

Munshi, Anupama, Thomas A. Buchholz, Khandan Keyomarsi, & Raymond E. Meyn. (2007). Activation of ER-α by DNMT and HDAC inhibitors radiosensitizes ER-α negative breast cancer cells. Cancer Research. 67. 3104–3104. 1 indexed citations

17.

Akli, Saïd, Carolyn S. Van Pelt, Tuyen Bui, et al.. (2007). Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway. Cancer Research. 67(15). 7212–7222. 61 indexed citations

18.

Efuet, Ekem T. & Khandan Keyomarsi. (2006). Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome. Cancer Research. 66(2). 1040–1051. 43 indexed citations

19.

Akli, Saïd, Asha S. Multani, Hannah F. Wingate, et al.. (2004). Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer. Cancer Research. 64(9). 3198–3208. 117 indexed citations

20.

Bacus, Sarah, Yosef Yarden, Moshe Oren, et al.. (1996). Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.. PubMed. 12(12). 2535–47. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact